• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Cadrenal Therapeutics Inc.

    6/15/26 8:16:55 PM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CVKD alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001405290
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    CADRENAL THERAPEUTICS, INC.
    SEC File Number
    Address of Issuer
    822 A1A NORTH
    SUITE 306
    PONTE VEDRA BEACH
    FLORIDA
    32082
    Phone
    904-300-0701
    Name of Person for Whose Account the Securities are To Be Sold
    Quang X. Pham
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Merrill Lynch
    824 A1A North
    Suite 200
    Ponte Vedra Beach � FL � 32082
    40000148400286824706/15/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common01/25/2022Founders SharesIssuerCheckbox not checked4000001/25/2022N/A

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Quang X. Pham
    830 A1A North
    Suite 196
    Ponte Vedra Beach � FL � 32082
    Common05/11/2026647637349.02
    Quang X. Pham
    830 A1A North
    Suite 196
    Ponte Vedra Beach � FL � 32082
    Common05/12/2026329817428.92
    Quang X. Pham
    830 A1A North
    Suite 196
    Ponte Vedra Beach � FL � 32082
    Common05/22/202611656627.7
    Quang X. Pham
    830 A1A North
    Suite 196
    Ponte Vedra Beach � FL � 32082
    Common05/28/2026298914739.78
    Quang X. Pham
    830 A1A North
    Suite 196
    Ponte Vedra Beach � FL � 32082
    Common05/29/20263031518.7
    Quang X. Pham
    830 A1A North
    Suite 196
    Ponte Vedra Beach � FL � 32082
    Common06/02/20263491555.82
    Quang X. Pham
    830 A1A North
    Suite 196
    Ponte Vedra Beach � FL � 32082
    Common06/03/202623239892.99
    Quang X. Pham
    830 A1A North
    Suite 196
    Ponte Vedra Beach � FL � 32082
    Common06/04/2026389817206.23
    Quang X. Pham
    830 A1A North
    Suite 196
    Ponte Vedra Beach � FL � 32082
    Common06/05/202620649124.36
    Quang X. Pham
    830 A1A North
    Suite 196
    Ponte Vedra Beach � FL � 32082
    Common06/08/2026589325815.88
    Quang X. Pham
    830 A1A North
    Suite 196
    Ponte Vedra Beach � FL � 32082
    Common06/09/20261299253298.99
    Quang X. Pham
    830 A1A North
    Suite 196
    Ponte Vedra Beach � FL � 32082
    Common06/10/2026350014717.5
    Quang X. Pham
    830 A1A North
    Suite 196
    Ponte Vedra Beach � FL � 32082
    Common06/11/202614626021.35
    Quang X. Pham
    830 A1A North
    Suite 196
    Ponte Vedra Beach � FL � 32082
    Common06/12/20261299651180.32

    144: Remarks and Signature

    Remarks
    Locking in the four-week average for week ending 6/12/26 for 332,006 shares.
    Date of Notice
    06/15/2026
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    09/23/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Quang X. Pham

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $CVKD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CVKD

    DatePrice TargetRatingAnalyst
    12/18/2023$4.00Outperform
    Noble Capital Markets
    More analyst ratings

    $CVKD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, CEO and Interim CFO Pham Quang X sold $13,110 worth of shares (4,126 units at $3.18) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 128,589 units (SEC Form 4)

    4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

    6/18/26 6:36:46 PM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, CEO and Interim CFO Pham Quang X sold $70,352 worth of shares (18,124 units at $3.88) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 132,715 units (SEC Form 4)

    4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

    6/15/26 8:58:15 PM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, CEO and Interim CFO Pham Quang X sold $93,294 worth of shares (22,385 units at $4.17) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 150,839 units (SEC Form 4)

    4 - Cadrenal Therapeutics, Inc. (0001937993) (Issuer)

    6/10/26 8:26:15 PM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CVKD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress

    Selection highlights the clinical value potential of Cadrenal’s first-in-class 12-lipoxygenase inhibitor for Heparin-Induced Thrombocytopenia (HIT) First-ever randomized, blinded, placebo-controlled trial in HIT, a life-threatening blood-clotting disorder triggered by an immune reaction to heparin, the most widely used blood thinner in hospitals Phase-3 ready and addresses a peak $2 billion annual revenue potential in the HIT market PONTE VEDRA, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company advancing late-stage novel therapies for life-threatening immune and thrombotic conditions, today announced that late-breaking clinica

    6/24/26 8:00:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease

    Company to present Phase 3-ready pipeline, 12-LOX platform, and pediatric rare-disease expansion to global pharmaceutical partners at the 2026 BIO International Convention in San Diego Kawasaki disease is the leading cause of acquired heart disease in children in developed nations. Patients are at risk of forming blood clots in coronary arteries and may require lifelong treatment If the designation is granted and tecarfarin is approved for this indication, Cadrenal would be eligible to receive a Priority Review Voucher—recent open-market valuations for these vouchers have reached into the ~$200 million range PONTE VEDRA, Fla., June 18, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc

    6/18/26 9:00:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026

    New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering discussionsAdditional billion-dollar target- Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI), a serious complication affecting 35,000 U.S. patients annually, with no approved FDA-approved targeted therapiesDual-Purpose Synergy - Planned Phase 2a proof-of-concept trial expected to generate safety, renal injury signals, and 12-LOX pathway biology in high-risk cardiac surgery patients, while generating high-value data potentially relevant to the Company's lead HIT indicationCapital-Efficient Development: Leverages shared in-hospital ICU infrastructure and an int

    6/15/26 8:30:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CVKD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Noble Capital Markets initiated coverage on Cadrenal Therapeutics with a new price target

    Noble Capital Markets initiated coverage of Cadrenal Therapeutics with a rating of Outperform and set a new price target of $4.00

    12/18/23 8:12:12 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CVKD
    SEC Filings

    View All

    Cadrenal Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

    6/18/26 9:02:06 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Cadrenal Therapeutics Inc.

    144 - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

    6/15/26 8:16:55 PM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cadrenal Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

    6/3/26 4:25:25 PM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CVKD
    Leadership Updates

    Live Leadership Updates

    View All

    Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

    PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development-stage card

    12/1/25 9:00:00 AM ET
    $CVKD
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

    James J. Ferguson, MD, FACC, FAHA, joins as Chief Medical Officer Extensive experience provides strong support for advancing specialized cardiovascular assets, including leading the late-stage clinical development of tecarfarin and other business development opportunities Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new Vitamin K antagonist, today announced a leadership transition appointing James J. Ferguson, MD, FACC, FAHA, as its new Chief Medical Officer, effective immediately. Dr. Ferguson is a distinguished medical expert with over 25

    2/6/25 9:00:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

    Lays out Phase 3 Clinical and Regulatory Path for Tecarfarin and Three-Year Strategic Plan Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), announced today its engagement in three key events leading up to and during the 43rd Annual J.P. Morgan Healthcare Conference Week, to be held on January 13-16, 2025 in San Francisco, California. Cadrenal Therapeutics is a biopharmaceutical company focused on developing tecarfarin, a novel oral vitamin K antagonist (VKA) in advanced clinical development and designed to be a superior and safer chronic anticoagulant therapeutic for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions. Quang X. Pham, Chairman and Chief

    12/18/24 9:00:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CVKD
    Financials

    Live finance-specific insights

    View All

    Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA

    PONTE VEDRA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today reported its financial results for the first quarter ended March 31, 2026, and provided a corporate update highlighting continued progress in its CAD-1005 program for HIT. The Company has now received the official minutes from its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), which provided guidance on key elements of the planned pivotal Phase 3 registration trial for CAD-1005, Cadrenal's investigational first-in-class 12-lipoxygenase (12-

    5/7/26 8:30:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting

    PONTE VEDRA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update highlighting recent progress across its CAD-1005 program for HIT and broader 12-LOX inhibitor platform. The update reflects continued progress for CAD-1005, Cadrenal's first-in-class 12-LOX inhibitor for suspected heparin-induced thrombocytopenia (HIT), including completion of its End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administra

    3/31/26 8:45:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

    Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing, distinguishing it from related compounds.Orphan Drug and Fast Track designations from the FDA PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced the acquisition of VLX-1005 and related 12-lipoxygenase (12-LOX) assets from Veralox Therapeutics ("Veralox"). The acquisition immediately strengthens Cadren

    12/11/25 8:05:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CVKD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cadrenal Therapeutics Inc.

    SC 13G/A - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

    11/14/24 4:00:17 PM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cadrenal Therapeutics Inc.

    SC 13G - Cadrenal Therapeutics, Inc. (0001937993) (Subject)

    10/4/24 4:15:02 PM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care